肠易激综合征的肠道菌群干预  

Management of microbiota in irritable bowel syndrome

作　　者：李铭[1] 李延青[1] 

机构地区：[1]山东大学齐鲁医院消化内科,山东济南250012

出　　处：《中国实用内科杂志》2016年第9期736-738,共3页Chinese Journal of Practical Internal Medicine

摘　　要：肠道菌群是人体的重要组成部分,并在肠易激综合征的发病过程中起到重要作用。近年来的研究表明,多种类型的微生态制剂能够对肠易激综合征起到治疗作用。文章总结了肠道菌群调节在肠易激综合征方面的循证医学证据,结合临床实践经验进行归纳,并提出肠道菌群干预应遵循"先破后立"的原则。The intestinal microbiota is an essential part of human body, which contributes significantly to the pathogenesis of irritable bowel syndrome. Recently, multiple types of microbial agents have been documented effective for irritable bowel syndrome. We summarized the clinical evidences about the microbiota modulation in IBS patients, and discussed it by combining with our clinical experience. We proposed a set-after-break strategy for microbiota modulation.

关 键 词：肠易激综合征 肠道菌群 

分 类 号：R574[医药卫生—消化系统]